[Effects of selective cyclooxygenase-2 inhibitor on proliferation and apoptosis of human bladder cancer cell line T24].
OBJECTIVE
Cyclooxygenase-2 (COX-2) is related closely to the tumorigenesis of bladder cancer, and COX-2 inhibitor has potential antitumor effect. This study was to investigate the effects of selective COX-2 inhibitors on the proliferation and apoptosis of human bladder cancer cell line T24.


METHODS
The effects of selective COX-2 inhibitors SC-58125 and celecoxib, and nonselective COX inhibitor indomethacin on the proliferation of T24 cells were evaluated by MTT assay. Cell apoptosis was determined by flow cytometry (FCM), DNA ladder electrophoresis, and fluorescent microscopy with Hoechst33258 staining. The expression of apoptosis-related genes Bcl-2 and Bax were analyzed by reverse transcription-polymerase chain reaction (RT-PCR).


RESULTS
Within concentrations of 12.5-200 micromol/L, SC-58125, celecoxib, and indomethacin could inhibit the proliferation of T24 cells to different extents. SC-58125 tended to be more effective than the other two. The 50% inhibition concentration (IC50) of SC-58125 was determined to be 25-50 micromol/L. The apoptosis of T24 cells was enhanced after exposure to SC-58125. When treated with 100 micromol/L SC-58125 for 6 and 12 h, the apoptosis rates of T24 cells were (7.95+/-1.88)% and (12.5+/-2.42)%, respectively, which were significantly higher than that of control cells (P<0.05). But the expression of Bcl-2 and Bax genes did not change.


CONCLUSIONS
Selective COX-2 inhibitor could inhibit the proliferation and induce the apoptosis of T24 cells.
Zhang
Jian
J
Department of Urology, The First Affiliated Hospital in Wuxi City, Nanjing Medical University, Wuxi, Jiangsu, 214002, PR China. uroistchang@21cn.com
Xu
Zhuo-Qun
ZQ
Hu
Qiang
Q
Qiu
Xue-Wen
XW
Wang
Zhi-Rong
ZR
D017209:Apoptosis / Q000187:drug effects*; D000068579:Celecoxib; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D005434:Flow Cytometry; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013449:Sulfonamides / Q000494:pharmacology; D001749:Urinary Bladder Neoplasms / Q000378:metabolism / Q000473:pathology*; D051028:bcl-2-Associated X Protein / Q000378:metabolism
D052246:Cyclooxygenase 2 Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D011720:Pyrazoles; D013449:Sulfonamides; D051028:bcl-2-Associated X Protein; C090859:1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole; D000068579:Celecoxib; D007213:Indomethacin